REGiMMUNE to present GvHD data at the 50th ASH Annual Meeting

December 05, 2008

Mountain View, CA - December 5, 2008 - REGiMMUNE Corporation, a privately held biopharmaceutical company focused on developing technologies and products for immune disorders, will present preclinical data on the company's potential therapeutic treatment for Graft versus Host Disease (GvHD) at the American Society of Hematology Annual Meeting being held December 6 through 9 in San Francisco, California. REGiMMUNE is developing KRN7000 (RGI-2001) as a new immunosuppressant for GvHD associated with stem cell transplantation. Two posters will be presented at ASH on the evenings of Sunday December 7 and Monday December 8, respectively.

Abstract/Poster II-426
Sunday, December 7: 6:00 PM - 8:00 PM
Donor-Specific Tolerance Induction through Expansion of DCregs and Tregs by a Liposomal Formulation of KRN7000 (RGI-2001)

Abstract/Poster III-582
Monday, December 8: 5:30 PM - 7:30 PM
A Liposomal Formulation of KRN7000 (RGI-2001) Potently Reduces GvHD Lethality through the Expansion of CD4+Foxp3+ Regulatory T cells in Murine Models.

"We are delighted to present our progress on RGI-2001 development at the 50th ASH Annual Meeting," said Mr. Haru Morita, President and Chief Executive Officer, REGiMMUNE. "This is a great opportunity to provide an update on our pre-IND stage product candidate, RGI-2001, which is in a preclinical study for GvHD associated with bone marrow transplantation. The company is also developing RGI-2001 for solid organ transplantation. Our mission is to develop novel therapies for immune disorders including allergies, autoimmune diseases and transplantation. We believe the success of RGI-2001 will be the first demonstration of the promise of our proprietary technology and of the company's significant development capabilities."
-end-
About REGiMMUNE

REGiMMUNE is a biotechnology company focused on the discovery, development and commercialization of immune regulatory therapeutics to treat life-threatening and debilitating conditions, including allergies, autoimmune diseases and inflammatory disorders. In addition to its potential for GvHD, ToleroVax is a therapeutic candidate for autoimmune diseases such as Multiple Sclerosis (MS) and Systemic Lupus, in which down-regulation of and/or dysfunction of regulatory T-cells lead to serious up-regulation of immunity against the auto-antigen. reVax is the company's second proprietary technology platform, which works by modulating the immune system by enhancing antigen-specific immune regulatory cells. This technique is expected to be useful in conditions such as Ragweed Allergy, Rheumatoid Arthritis and MS, where control of an abnormal immune response is desirable. reVax is being utilized to advance several compounds through clinical development and eventual commercialization of a broad range of products for REGiMMUNE and its partners. The company is headquartered in Tokyo, Japan and has a U.S. subsidiary in Mountain View, California.. For more information, visit www.regimmune.com.

About the ASH Annual Meeting

Held annually in December, the Society's annual meeting provides hematologists from around the world a forum for discussing critical issues in hematology. More than 21,000 clinicians, scientists, and others attend the four-day meeting, which consists of a superb educational program and cutting-edge scientific sessions. The annual meeting features oral and poster presentations that are chosen by peer-reviewers from abstracts submitted prior to the meeting and contain the latest and most exciting developments in scientific research. Plenary symposia and named lectures on specialized areas of hematology are also presented throughout the meeting program.

REGiMMUNE

Related Transplantation Articles from Brightsurf:

A revolutionary new treatment alternative to corneal transplantation
A new approach in ophthalmology that offers a revolutionary alternative to corneal transplantation has just been developed by researchers and clinicians in North America, Europe, and Oceania.

Fewer complications after organ transplantation
A large international study coordinated by University Hospital Regensburg and Charité - Universitätsmedizin Berlin has demonstrated the safety of new cell therapy approaches for use in kidney transplant recipients.

Elderly patients also benefit from kidney transplantation
So far, kidney transplantation has generally not been offered to elderly patients (>75 years) because of the perioperative risks.

New material will allow abandoning bone marrow transplantation
Scientists from the National University of Science and Technology 'MISIS' developed nanomaterial, which will be able to restore the internal structure of bones damaged due to osteoporosis and osteomyelitis.

Fewer medical tests -- timely listing for transplantation
Younger patients would benefit greatly from kidney transplantation. Their expected remaining lifetime may even be doubled by having a transplant.

Uterus transplantation -- ethically just as problematic as altruistic surrogacy
In 2014, the first child to have been gestated in a donated uterus was born.

Advancing transplantation: Hepatitis C-infected organs safe for transplantation when followed by antiviral treatment
Twenty patients at Penn Medicine have been cured of the hepatitis C virus (HCV) following lifesaving kidney transplants from deceased donors who were infected with the disease, according to a study published today in Annals of Internal Medicine.

Transplantation followed by antiviral therapy cured hepatitis C
Twenty patients who received kidneys transplanted from hepatitis C virus (HCV)-infected donors experienced HCV cure, good quality of life, and excellent renal function at one year.

The Journal of Heart and Lung Transplantation: 50 years of heart transplantation progress
This month marks the 50th anniversary of the world's first human heart transplant performed at Groote Schuur Hospital in Cape Town by South African surgeon, Christiaan Barnard.

Older donor lungs should be considered for transplantation
With a scarcity of lungs available for transplantation, the use of lungs from donors older than age 60 has been shown to achieve reasonable outcomes and should be considered as a viable option, according to research published online today in The Annals of Thoracic Surgery.

Read More: Transplantation News and Transplantation Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.